Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
IL-13 is a driver of COVID-19 severity.
Donlan AN, Sutherland TE, Marie C, Preissner S, Bradley BT, Carpenter RM, Sturek JM, Ma JZ, Moreau GB, Donowitz JR, Buck GA, Serrano MG, Burgess SL, Abhyankar MM, Mura C, Bourne PE, Preissner R, Young MK, Lyons GR, Loomba JJ, Ratcliffe SJ, Poulter MD, Mathers AJ, Day A, Mann BJ, Allen JE, Petri WA Jr. Donlan AN, et al. Among authors: sturek jm. medRxiv [Preprint]. 2021 Mar 1:2020.06.18.20134353. doi: 10.1101/2020.06.18.20134353. medRxiv. 2021. PMID: 33688686 Free PMC article. Updated. Preprint.
Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19.
Jensen TO, Grandits GA, Jain MK, Murray TA, Grund B, Shaw-Saliba K, Matthay MA, Abassi M, Ardelt M, Baker JV, Chen P, Dewar RL, Goodman AL, Hatlen TJ, Highbarger HC, Holodniy M, Lallemand P, Laverdure S, Leshnower BG, Looney D, Moschopoulos CD, Mugerwa H, Murray DD, Mylonakis E, Nagy-Agren S, Rehman MT, Rupert A, Stevens RA, Turville S, Weintrob A, Wick K, Lundgren J, Ko ER; ACTIV-3/TICO Study Group. Jensen TO, et al. J Infect Dis. 2024 Mar 14;229(3):671-679. doi: 10.1093/infdis/jiad446. J Infect Dis. 2024. PMID: 37948759 Free PMC article. Clinical Trial.
Evaluation of K18-hACE2 Mice as a Model of SARS-CoV-2 Infection.
Moreau GB, Burgess SL, Sturek JM, Donlan AN, Petri WA, Mann BJ. Moreau GB, et al. Among authors: sturek jm. Am J Trop Med Hyg. 2020 Sep;103(3):1215-1219. doi: 10.4269/ajtmh.20-0762. Am J Trop Med Hyg. 2020. PMID: 32723427 Free PMC article.
Convalescent plasma for preventing critical illness in COVID-19: A phase 2 trial and immune profile.
Sturek JM, Thomas TA, Gorham JD, Sheppard CA, Raymond AE, Guex KP, Harrington WB, Barros AJ, Madden GR, Alkabab YM, Lu D, Liu Q, Poulter MD, Mathers AJ, Thakur A, Kubicka EM, Lum LG, Heysell SK. Sturek JM, et al. medRxiv [Preprint]. 2021 Feb 19:2021.02.16.21251849. doi: 10.1101/2021.02.16.21251849. medRxiv. 2021. PMID: 33619508 Free PMC article. Updated. Preprint.
IL-13 is a driver of COVID-19 severity.
Donlan AN, Sutherland TE, Marie C, Preissner S, Bradley BT, Carpenter RM, Sturek JM, Ma JZ, Moreau GB, Donowitz JR, Buck GA, Serrano MG, Burgess SL, Abhyankar MM, Mura C, Bourne PE, Preissner R, Young MK, Lyons GR, Loomba JJ, Ratcliffe SJ, Poulter MD, Mathers AJ, Day AJ, Mann BJ, Allen JE, Petri WA Jr. Donlan AN, et al. Among authors: sturek jm. JCI Insight. 2021 Aug 9;6(15):e150107. doi: 10.1172/jci.insight.150107. JCI Insight. 2021. PMID: 34185704 Free PMC article.
Convalescent Plasma for Preventing Critical Illness in COVID-19: a Phase 2 Trial and Immune Profile.
Sturek JM, Thomas TA, Gorham JD, Sheppard CA, Raymond AH, Petros De Guex K, Harrington WB, Barros AJ, Madden GR, Alkabab YM, Lu DY, Liu Q, Poulter MD, Mathers AJ, Thakur A, Schalk DL, Kubicka EM, Lum LG, Heysell SK. Sturek JM, et al. Microbiol Spectr. 2022 Feb 23;10(1):e0256021. doi: 10.1128/spectrum.02560-21. Epub 2022 Feb 23. Microbiol Spectr. 2022. PMID: 35196802 Free PMC article. Clinical Trial.
Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients with Moderate to Severe COVID 19: A Phase IIa Trial.
Sasson J, Donlan AN, Ma JZ, Haughey HM, Coleman R, Nayak U, Mathers AJ, Laverdure S, Dewar R, Jackson PEH, Heysell SK, Sturek JM, Petri WA Jr. Sasson J, et al. Among authors: sturek jm. medRxiv [Preprint]. 2022 May 19:2022.03.30.22273194. doi: 10.1101/2022.03.30.22273194. medRxiv. 2022. PMID: 35411349 Free PMC article. Updated. Preprint.
Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019: A Phase 2a Trial.
Sasson J, Donlan AN, Ma JZ, Haughey HM, Coleman R, Nayak U, Mathers AJ, Laverdure S, Dewar R, Jackson PEH, Heysell SK, Sturek JM, Petri WA Jr. Sasson J, et al. Among authors: sturek jm. Open Forum Infect Dis. 2022 Jul 27;9(8):ofac343. doi: 10.1093/ofid/ofac343. eCollection 2022 Aug. Open Forum Infect Dis. 2022. PMID: 35959207 Free PMC article.
Pulmonary function and survival one year after dupilumab treatment of acute moderate to severe COVID-19: A follow up study from a Phase IIa trial.
Hendrick J, Ma JZ, Haughey HM, Coleman R, Nayak U, Kadl A, Sturek JM, Jackson P, Young MK, Allen JE, Petri WA Jr. Hendrick J, et al. Among authors: sturek jm. medRxiv [Preprint]. 2023 Sep 2:2023.09.01.23293947. doi: 10.1101/2023.09.01.23293947. medRxiv. 2023. PMID: 37693596 Free PMC article. Updated. Preprint.
41 results